Introduction: Methotrexate (MTX) acts by suppressing multiple immune pathways involved in the pathogenesis of lichen planus (LP). Trials assessing the efficacy and relapse rates of methotrexate in LP are lacking.
Objectives: Our objective was to analyze the efficacy and safety of low-dose methotrexate in generalized and recalcitrant LP patients retrospectively and to assess the relapse rates in patients after stopping MTX therapy.
There are conflicting reports regarding the roles of T helper-17 (Th17) and T regulatory (Treg) cells in type 1 leprosy reactions (T1Rs). Also, literature on the correlation of immunological parameters with a validated scoring system and the effect of treatment on cytokines is lacking. Adult patients with untreated T1R and nonreactional spectrum-matched controls were included in the study for comparison of levels of Th17 and Treg pathway cytokines in serum, skin lesions (reactional), and peripheral blood mononuclear cells (PBMCs) culture supernatants.
View Article and Find Full Text PDFIndian J Dermatol Venereol Leprol
September 2024